AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

Post-LOE

amlodipine,valsartan and hydrochlorothiazide

Macleods Pharms

ANDAORALTABLET

Approved

Jan 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE (amlodipine,valsartan and hydrochlorothiazide) by Macleods Pharms is angiotensin 2 receptor antagonists [moa]. Approved for hypertension, to lower blood pressure, hypertension to lower blood pressure and 1 more indications. First approved in 2025.

Drug data last refreshed 14h ago

Mechanism of Action

Angiotensin 2 Receptor Antagonists

Pharmacologic Class:

Angiotensin 2 Receptor Blocker

Indications (4)

hypertension to lower blood pressure

Worked on AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE at Macleods Pharms? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.